Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer
CONCLUSION: We describe the challenges and approaches to operationalize complex, real-world data to identify intended chemotherapy regimens in large, observational studies. This methodology can improve efficiency of use of large-scale clinical data in real-world populations, helping answer critical questions to improve care delivery and patient outcomes.PMID:38635936 | DOI:10.1200/CCI.23.00209 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Jenna Bhimani Kelli O'Connell Isaac J Ergas Marilyn Foley Grace B Gallagher Jennifer J Griggs Narre Heon Tatjana Kolevska Yuriy Kotsurovskyy Candyce H Kroenke Cecile A Laurent Raymond Liu Kanichi G Nakata Sonia Persaud Donna R Rivera Janise M Roh Sara Tab Source Type: research
Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer
In this study, the bifunctional HDAC and DNMT inhibitor J208 exhibited antitumour activity in TNBC cell lines. J208 effectively induced apoptosis and cell cycle arrest at the G0/G1 phase, inhibiting cell migration and invasion in TNBC. Moreover, this bifunctional inhibitor induced the expression of endogenous retroviruses (ERVs) and elicited a viral mimicry response, which increased the intracellular levels of double-stranded RNA (dsRNA) to activate the innate immune signalling pathway in TNBC. In summary, we demonstrated that the bifunctional inhibitor J208, which is designed to inhibit HDAC and DNMT, has potent anticance...
Source: European Journal of Pharmaceutical Sciences - April 18, 2024 Category: Drugs & Pharmacology Authors: Weiwen Fan Wenkai Li Lulu Li Meirong Qin Chengzhou Mao Zigao Yuan Ping Wang Bizhu Chu Yuyang Jiang Source Type: research
Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer
CONCLUSION: We describe the challenges and approaches to operationalize complex, real-world data to identify intended chemotherapy regimens in large, observational studies. This methodology can improve efficiency of use of large-scale clinical data in real-world populations, helping answer critical questions to improve care delivery and patient outcomes.PMID:38635936 | DOI:10.1200/CCI.23.00209 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Jenna Bhimani Kelli O'Connell Isaac J Ergas Marilyn Foley Grace B Gallagher Jennifer J Griggs Narre Heon Tatjana Kolevska Yuriy Kotsurovskyy Candyce H Kroenke Cecile A Laurent Raymond Liu Kanichi G Nakata Sonia Persaud Donna R Rivera Janise M Roh Sara Tab Source Type: research
Methodology for Using Real-World Data From Electronic Health Records to Assess Chemotherapy Administration in Women With Breast Cancer
CONCLUSION: We describe the challenges and approaches to operationalize complex, real-world data to identify intended chemotherapy regimens in large, observational studies. This methodology can improve efficiency of use of large-scale clinical data in real-world populations, helping answer critical questions to improve care delivery and patient outcomes.PMID:38635936 | DOI:10.1200/CCI.23.00209 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 18, 2024 Category: Cancer & Oncology Authors: Jenna Bhimani Kelli O'Connell Isaac J Ergas Marilyn Foley Grace B Gallagher Jennifer J Griggs Narre Heon Tatjana Kolevska Yuriy Kotsurovskyy Candyce H Kroenke Cecile A Laurent Raymond Liu Kanichi G Nakata Sonia Persaud Donna R Rivera Janise M Roh Sara Tab Source Type: research
Bifunctional HDAC and DNMT inhibitor induces viral mimicry activates the innate immune response in triple-negative breast cancer
In this study, the bifunctional HDAC and DNMT inhibitor J208 exhibited antitumour activity in TNBC cell lines. J208 effectively induced apoptosis and cell cycle arrest at the G0/G1 phase, inhibiting cell migration and invasion in TNBC. Moreover, this bifunctional inhibitor induced the expression of endogenous retroviruses (ERVs) and elicited a viral mimicry response, which increased the intracellular levels of double-stranded RNA (dsRNA) to activate the innate immune signalling pathway in TNBC. In summary, we demonstrated that the bifunctional inhibitor J208, which is designed to inhibit HDAC and DNMT, has potent anticance...
Source: European Journal of Pharmaceutical Sciences - April 18, 2024 Category: Drugs & Pharmacology Authors: Weiwen Fan Wenkai Li Lulu Li Meirong Qin Chengzhou Mao Zigao Yuan Ping Wang Bizhu Chu Yuyang Jiang Source Type: research
Assessment of change in the basic variants composition of trastuzumab during dilution in saline for administration
Eur J Pharm Biopharm. 2024 Apr 16:114295. doi: 10.1016/j.ejpb.2024.114295. Online ahead of print.ABSTRACTPostproduction handling of drug products during preparation or clinical use may affect the structure and efficacy of the drug and perhaps remain unnoticed. Since chemical modifications can impact the product's structure, stability, and biological activity, this study investigates the impact of elevated temperature and subtle shift in pH on the drug product post-dilution in saline. The mAb sample diluted in saline for administration was stressed at elevated temperature and slightly acidic pH condition. Extended stability...
Source: European Journal of Pharmaceutics and Biopharmaceutics - April 18, 2024 Category: Drugs & Pharmacology Authors: Surbhi Gupta Christian Sch öneich Anurag S Rathore Source Type: research
Inflammatory breast cancer: Epidemiologic data and therapeutic results
In this study, we reviewed the literature using the Surveillance, Epidemiology, and End Results (SEER) database compared to other published series. We observed that in the high incidence areas (North of Africa) when compared to "classical" breast cancer, IBC was associated to younger age (less than 50 years) with rapid evolution of signs and symptoms (in less than 3 up to 6 months), and more aggressive clinical and histopathological-molecular parameters, due to the predominance of triple-negative and HER2+ subtypes in around 60% of cases. An epidemiologic trend was observed in both high and low incidence areas since the ei...
Source: International Review of Cell and Molecular Biology - April 18, 2024 Category: Cytology Authors: Hamouda Boussen Yosra Berrazaga None Sherif Kullab Maroua Manai Narjess Berrada Nesrine Mejri Ismail Siala Paul H Levine Massimo Cristofanilli Source Type: research
Inflammatory breast cancer: An overview about the histo-pathological aspect and diagnosis
Int Rev Cell Mol Biol. 2024;384:47-61. doi: 10.1016/bs.ircmb.2024.02.001. Epub 2024 Mar 29.ABSTRACTInflammatory Breast Cancer (IBC) is a rare and aggressive form of locally advanced breast cancer, classified as stage T4d according to the tumor-node-metastasis staging criteria. This subtype of breast cancer is known for its rapid progression and significantly lower survival rates compared to other forms of breast cancer. Despite its distinctive clinical features outlined by the World Health Organization, the histopathological characteristics of IBC remain not fully elucidated, presenting challenges in its diagnosis and trea...
Source: International Review of Cell and Molecular Biology - April 18, 2024 Category: Cytology Authors: Ghada Sahraoui Nabil Rahoui Maha Driss Karima Mrad Source Type: research
Primary salivary duct carcinoma of the lung: clinicopathological features, diagnosis and practical challenges
Conclusions
LSDC is a highly rare malignant tumour. The distinctive architecture of in situ carcinoma and tumour cells expressing AR can provide diagnostic indications for LSDC. (Source: Journal of Clinical Pathology)
Source: Journal of Clinical Pathology - April 18, 2024 Category: Pathology Authors: Li, S., Hou, L., Huang, Y., Wu, W., Wu, C., Zhang, L. Tags: Original research Source Type: research
New | phs003275.v1.p1 | Prediction of Resistance and Sensitivity to HER2 Targeted Therapy in the Neoadjuvant Setting
Prediction of Resistance and Sensitivity to HER2 Targeted Therapy in the Neoadjuvant Setting (study page |release notes) (Source: dbGaP, the database of Genotypes and Phenotypes)
Source: dbGaP, the database of Genotypes and Phenotypes - April 17, 2024 Category: Genetics & Stem Cells Tags: StudyRelease Source Type: research
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947 (Source: Cell Research)
Source: Cell Research - April 17, 2024 Category: Cytology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research
Chlordiazepoxide against signalling, receptor and regulatory proteins of breast cancer: a structure-based in-silico approach
In this study, we included four crucial proteins that perform signalling, receptor, and regulatory action, namely- NUDIX Hydrolases, Dihydrofolate Reductase, HER2/neu Kinase and EGFR and performed multitargeted molecular docking studies against human-approved drugs using HTVS, SP and extra precise algorithms and filtered the poses with MM\GBSA, suggested a benzodiazepine derivative chlordiazepoxide, used as an anxiolytic agent, can be a multitargeted inhibitor with docking and MM\GBSA score ranging from - 4.628 to - 7.877 and - 18.59 to - 135.86 kcal/mol, respectively, and the most interacted residues were 6ARG, 6GLU, 3TRP...
Source: Molecular Medicine - April 17, 2024 Category: Molecular Biology Authors: Ahad Amer Alsaiari Amal F Gharib Maha Mahfouz Bakhuraysah Amani A Alrehaili Shatha M Algethami Hayfa Ali Alsaif Norah Al Harthi Mohammed Ageeli Hakami Source Type: research
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947 (Source: Cancer Control)
Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947 (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research
Maintenance pembrolizumab therapy in patients with metastatic HER2-negative breast cancer with prior response to chemotherapy
CONCLUSIONS: Pembrolizumab monotherapy achieved durable treatment responses. Patients with a high baseline T-cell clonality had prolonged disease control with pembrolizumab.PMID:38629963 | DOI:10.1158/1078-0432.CCR-23-2947 (Source: Clinical Breast Cancer)
Source: Clinical Breast Cancer - April 17, 2024 Category: Cancer & Oncology Authors: Toshiaki Iwase Evan N Cohen Hui Gao Angela Alexander Megumi Kai Vivian Chiv Xiaoping Wang Savitri Krishnamurthy Diane Liu Yu Shen Kumiko Kida Alexandre Reuben Rachel Layman David Ramirez Debu Tripathy Stacy L Moulder Clinton Yam Vicente Valero Bora Lim Ja Source Type: research
